Personalis (PSNL) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Personalis (PSNL) has outperformed Sera Prognostics (SERA) over the past year, gaining 111.4% versus a loss of 36.3%. Over five years, PSNL leads with a -19.8% price change compared with -80.9% for SERA. Personalis is the larger company by market cap ($1.71 billion vs $81.7 million), about 20.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PSNL | SERA |
|---|---|---|
| Share price | $16.00 | $2.07 |
| Market cap | $1.71B | $81.66M |
| 1-day change | -0.19% | +0.98% |
| YTD return | +101.01% | -29.83% |
| 1-year return | +111.36% | -36.31% |
| 5-year return | -19.76% | -80.92% |
| EPS (TTM) | $-1.09 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.89 | $3.95 |
| 52-week low | $4.96 | $1.56 |
| Distance from 52-week high | -15.30% | -47.59% |
| Analyst consensus | hold | — |
| Avg. price target upside | -5.19% | — |
| Average volume | 3.60M | 28.59K |
| Shares outstanding | 106.80M | 38.48M |
| Employees | 259 | — |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Personalis is about 20.9 times larger than Sera Prognostics by market value ($1.71B vs $81.66M).
- PSNL has outperformed SERA by 147.7 percentage points over the past year.
About Personalis
PSNL stock →Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Health Care · Medical Specialities · 259 employees
PSNL vs SERA FAQ
Which is bigger, Personalis or Sera Prognostics?
Personalis (PSNL) is larger, with a market capitalization of $1.71B compared with $81.66M for Sera Prognostics (SERA).
Which stock has performed better over the past year, PSNL or SERA?
PSNL returned +111.36% over the past 12 months, compared with -36.31% for SERA (price return, excluding dividends). Past performance does not predict future results.
Are Personalis and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.